← Evolent Health, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $254.2m |
$434.9m
+71.11%
|
$627.1m
+44.17%
|
$846.4m
+34.98%
|
$1.0b
+20.80%
|
$908.0m
-11.20%
|
$1.4b
+48.91%
|
$2.0b
+45.26%
|
$2.6b
+30.09%
|
$1.9b
-26.56%
|
$2.1b
+11.77%
|
|
| Cost of Goods and Services Sold | $155.2m |
$269.4m
+73.58%
|
$327.8m
+21.71%
|
$513.1m
+56.50%
|
$701.4m
+36.70%
|
$657.6m
-6.25%
|
$1.0b
+57.47%
|
$1.5b
+45.20%
|
$2.2b
+45.49%
|
$1.5b
-32.51%
|
$1.7b
+17.55%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | — | — | $1.0b | — | — | — | $1.7b | |
| Cost of revenue | $155.2m |
$269.4m
+73.58%
|
$327.8m
+21.71%
|
$513.1m
+56.50%
|
$701.4m
+36.70%
|
$657.6m
-6.25%
|
$1.0b
+57.47%
|
$1.5b
+45.20%
|
$2.2b
+45.49%
|
$1.5b
-32.51%
|
$1.7b
+17.55%
|
|
| Gross Profit (Calculated) (derived) | $99.0m |
$165.6m
+67.25%
|
$299.2m
+80.70%
|
$333.3m
+11.39%
|
$321.1m
-3.68%
|
$250.4m
-22.01%
|
$316.6m
+26.43%
|
$460.5m
+45.45%
|
$367.4m
-20.22%
|
$399.9m
+8.86%
|
— | |
| Interest Income (Expense), Net | $723k | — | — | — | — | — | — | — | — | — | $3.5m | |
| Research and Development Expense | $11.1m | $17.2m | $18.2m | $19.8m | $15.1m | $15.5m | — | — | — | — | — | |
| Selling, General and Administrative Expense | $160.7m | $205.7m | $235.4m | $257.0m | $222.6m | $219.5m | $269.3m | $358.1m | $263.1m | $303.9m | $291.9m | |
| Amortization of Intangible Assets | $12.5m | $22.8m | $27.2m | $37.7m | $32.9m | $29.4m | $35.2m | $91.0m | $88.1m | $89.6m | — | |
| Operating Expenses | $491.6m | $507.8m | $674.5m | $1.2b | $1.3b | $950.4m | $1.3b | $2.0b | $2.6b | $2.3b | $2.1b | |
| Operating Income (Loss) | ($237.4m) |
($72.8m)
+69.32%
|
($47.5m)
+34.82%
|
($306.6m)
-545.77%
|
($270.6m)
+11.74%
|
($42.4m)
+84.33%
|
$3.6m
+108.59%
|
($71.2m)
-2055.27%
|
($40.5m)
+43.15%
|
($410.1m)
-913.06%
|
($42.0m)
+89.75%
|
|
| Other Operating Income (Expense), Net | $4k | $171k | $109k | ($492k) | ($119k) | ($146k) | $3.6m | ($71.2m) | ($40.5m) | ($410.1m) | ($42.0m) | |
| Investment Income, Interest | $970k | $1.7m | $3.4m | $4.0m | $3.2m | $407k | $1.4m | $5.3m | $5.5m | $4.2m | — | |
| Interest income | $970k | $1.7m | $3.4m | $4.0m | $3.2m | $407k | $1.4m | $5.3m | $5.5m | $4.2m | $3.5m | |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | — | — | — | — | — | ($52.5m) | — | |
| Gain (loss) from equity method investees | ($841k) | ($1.8m) | ($4.7m) | ($9.5m) | $10.0m | $13.2m | $4.6m | $1.3m | ($3.4m) | $365k | — | |
| Other Nonoperating Income (Expense) | — | — | $109k | ($492k) | ($119k) | ($146k) | $57k | ($543k) | $241k | $249k | — | |
| Income (Loss) from Equity Method Investments | ($841k) | ($1.8m) | ($4.7m) | ($9.5m) | $10.0m | $13.2m | $4.6m | $1.3m | ($3.4m) | $365k | — | |
| Other expense, net | — | — | — | ($489k) | ($118k) | ($146k) | $57k | ($543k) | $241k | $249k | — | |
| Interest Expense (non-operating) | $247k | $3.6m | $5.5m | $14.5m | $28.3m | $25.4m | $15.6m | $54.2m | $24.7m | $57.5m | $65.7m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $237.5m | $76.4m | $54.2m | ($328.2m) | ($339.6m) | ($32.7m) | ($66.1m) | ($206.3m) | ($68.4m) | ($540.0m) | ($502.1m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($237.5m) | ($76.4m) | ($54.2m) | ($327.1m) | ($337.8m) | ($29.8m) | ($62.1m) | ($202.4m) | ($63.0m) | ($534.6m) | ($502.1m) | |
| Benefit from income taxes | ($10.8m) | ($6.6m) | $40k | ($21.5m) | ($3.6m) | $483k | ($43.4m) | ($89.4m) | ($1.4m) | ($126k) | — | |
| Current Income Tax Expense (Benefit) | $0 | $634k | $718k | $1.6m | ($2.4m) | $1.0m | $2.2m | $3.9m | $1.6m | $2.9m | $2.9m | |
| Net loss attributable to common shareholders of Evolent Health, Inc. - basic | ($159.7m) | ($60.7m) |
($52.7m)
+13.20%
|
($302.0m) | ($334.2m) | ($37.6m) | ($19.2m) | ($142.3m) | ($93.5m) | ($579.4m) | — | |
| Net loss attributable to common shareholders of Evolent Health, Inc. - diluted | ($159.7m) | ($60.7m) |
($52.7m)
+13.20%
|
($302.0m) | ($334.2m) | ($37.6m) | ($19.2m) | ($142.3m) | ($93.5m) | ($579.4m) | — | |
| Net Income (Loss) Attributable to Parent | ($159.7m) |
($60.7m)
+62.02%
|
($52.7m)
+13.20%
|
($302.0m)
-473.46%
|
($334.2m)
-10.69%
|
($37.6m)
+88.75%
|
($19.2m)
+49.03%
|
($113.0m)
-489.86%
|
($61.6m)
+45.49%
|
($534.5m)
-767.39%
|
($511.1m)
+4.39%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | ($159.7m) |
($60.7m)
+62.02%
|
($52.7m)
+13.20%
|
($302.0m)
-473.46%
|
($334.2m)
-10.69%
|
($37.6m)
+88.75%
|
($19.2m)
+49.03%
|
($142.3m)
-642.33%
|
($93.5m)
+34.31%
|
($579.4m)
-519.99%
|
($511.1m)
+11.80%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | ($67.0m) | ($9.1m) | ($1.5m) | ($3.6m) | $0 | $0 | ($46.0m) | ($62.0m) | ($173k) | ($804k) | ($511.1m) | |
| Preferred Stock Dividends and Other Adjustments | — | — | — | — | — | — | — | $29 | $32 | $45 | $54.7m | |
| Preferred Stock Dividends, Income Statement Impact | $0 | $0 | ($52.7m) | ($302.0m) | ($334.2m) | ($37.6m) | ($19.2m) | ($113.0m) | ($61.6m) | ($534.5m) | $54.7m | |
| Income (Loss) from Continuing Operations, Per Basic Share | ($4) | ($1) | — | ($4) | ($4) | ($0) | ($0) | ($1) | ($1) | ($5) | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | ($4) | ($1) | — | ($4) | ($4) | ($0) | ($0) | ($1) | ($1) | ($5) | — | |
| Earnings Per Share, Basic | ($3.55) | ($0.94) | ($0.68) | ($3.67) | ($3.94) | ($0.44) | ($0.20) | ($1.28) | ($0.81) | ($5.07) | ($4.49) | |
| Earnings Per Share, Diluted | ($3.55) | ($0.94) | ($0.68) | ($3.67) | ($3.94) | ($0.44) | ($0.20) | ($1.28) | ($0.81) | ($5.07) | ($4.49) | |
| Basic (in shares) | $45.0m | $64.4m | — | $82.4m | $84.9m | $86.1m | $93.7m | $111.3m | $114.7m | $114.2m | $112.5m | |
| Diluted (in shares) | $45.0m | $64.4m | — | $82.4m | $84.9m | $86.1m | $93.7m | $111.3m | $114.7m | $114.2m | $112.5m | |
| Weighted Average Number of Shares Outstanding, Basic | 45.0m | 64.4m | — | $82.4m | $84.9m | 86.1m | 93.7m | 111.3m | 114.7m | 114.2m | 112.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | 45.0m | 64.4m | — | $82.4m | $84.9m | 86.1m | 93.7m | 111.3m | 114.7m | 114.2m | 112.5m | |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, Amortization | $1.4m | $4.9m | $12.4m | $18.7m | $24.3m | $26.5m | $27.0m | $26.7m | $25.6m | $23.2m | — | |
| Costs and Expenses | $491.6m | $507.8m | $674.5m | $1.2b | $1.3b | $950.4m | $1.3b | $2.0b | $2.6b | $2.3b | — | |
| Goodwill, Impairment Loss | $160.6m | $0 | $0 | $199.8m | $215.1m | $0 | $0 | $0 | $0 | $398.0m | $398.0m | |
| Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims | — | — | — | — | — | — | $594.2m | $891.1m | $1.5b | $907.3m | — | |
| Depreciation and amortization expenses | $17.2m | $32.4m | $44.5m | $60.9m | $61.5m | $60.0m | $67.2m | $123.4m | $118.4m | $115.9m | $111.8m | |
| Loss on lease termination | — | — | — | — | — | — | $0 | $0 | $18.9m | $676k | — | |
| (Gain) loss on disposal of non-strategic assets | — | — | — | — | — | $0 | $0 | $8.1m | $0 | ($14.9m) | — | |
| Right-of-use asset impairment | — | — | — | — | — | $0 | $0 | $24.1m | $2.6m | $0 | — | |
| Goodwill impairment | $160.6m | $0 | $0 | $199.8m | $215.1m | $0 | $0 | $0 | $0 | $398.0m | $398.0m | |
| Change in fair value of contingent consideration | ($2.1m) | $400k | ($4.1m) | ($4.0m) | $3.9m | $13.3m | ($23.5m) | $18.0m | $4.9m | $6.5m | — | |
| Loss on extinguishment/repayment of debt | — | — | $0 | $0 | ($4.8m) | $0 | ($10.2m) | ($21.0m) | $0 | ($3.5m) | — | |
| Loss on option exercise | — | — | — | — | — | — | — | $0 | $0 | ($52.5m) | — | |
| Extinguishment of Series A Preferred Stock and other refinancing fees | — | — | — | — | — | — | — | $0 | $0 | ($15.0m) | — | |
| Change in tax receivables agreement liability | ($67.0m) | ($9.1m) | ($1.5m) | ($3.6m) | $0 | $0 | ($46.0m) | ($62.0m) | ($173k) | ($804k) | — | |
| Income (loss) before preferred dividends and accretion of Series A Preferred Stock | ($160) | ($61) | ($53) | ($302) | ($334) | ($38) | ($19) | ($113) | ($62) | ($535) | — | |
| Dividends and accretion of Series A Preferred Stock including excise tax | — | — | — | — | — | $0 | $0 | ($29.2m) | ($31.8m) | ($44.9m) | — | |
| Foreign currency translation adjustment | $0 | $0 | ($182k) | ($52k) | ($44k) | ($84k) | ($816k) | ($79k) | ($496k) | ($871k) | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | ($18.7m) | ($113.0m) | ($61.6m) | — | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | ($30.3m) | — | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | ($7.3m) | ($463k) | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | ($463k) | $0 | $0 | — | — | |
| Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. | ($159.7m) | ($60.7m) | ($52.8m) | ($302.0m) | ($334.3m) | ($37.7m) | ($20.0m) | ($142.3m) | ($94.0m) | ($580.3m) | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.